Antidenaturant drugs for cataract and other condensation diseases
Medical Hypotheses, ISSN: 0306-9877, Vol: 56, Issue: 1, Page: 114-120
2001
- 12Citations
- 7Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations12
- Citation Indexes12
- 12
- CrossRef11
- Captures7
- Readers7
Article Description
‘Condensation diseases’ are heterogeneous pathological conditions in which the primary pathogenetic step is the loss of solubility of specific substances, resulting in the formation of a condensed phase. Typical examples are cataract, nephrolithiasis, gallstone disease and certain rheumatic conditions in which protein denaturation, aggregation and precipitation may occur. Since the condensing molecules are often proteins, antidenaturant agents should be considered rational drugs for the treatment of these diseases. Surprisingly, however, only a few molecules with these properties are currently available for therapeutic use, including bendazac for cataract.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0306987700911289; http://dx.doi.org/10.1054/mehy.2000.1128; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0035169731&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/11133267; https://linkinghub.elsevier.com/retrieve/pii/S0306987700911289; https://dx.doi.org/10.1054/mehy.2000.1128
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know